Regeneron Pharmaceuticals Inc (REGN) Price

Pfizer Chases $48B Obesity Market With $2.1B Licensing Deal

Pfizer signed a $2.1 billion licensing deal with China's YaoPharma to develop a GLP-1 weight loss pill, marking a significant investment to capture a share of the growing obesity treatment market.

Regeneron Growth Stalls as ServiceNow and Progressive Gain Favor

StockStory recommends selling Regeneron (REGN) due to its revenue growth slowing to 4.3% annually, while advising to buy ServiceNow (NOW) and Progressive (PGR) based on strong performance metrics.

Alvotech Launches $100M Bond to Fund Biosimilar Pipeline

Alvotech (NASDAQ: ALVO) launched a $100 million convertible bond offering to fund its biosimilar pipeline and global expansion. The move comes as the company reaffirms 2025 guidance and sets ambitious 2026 targets, despite acknowledging potential U.S. regulatory delays.

GSK Pipeline Gains Momentum on Regulatory Wins

GSK plc is gaining significant investor attention after a series of positive regulatory updates in the U.S. and EU for key pipeline assets. These catalysts, combined with an imminent CEO transition, are reshaping the company's narrative from a stable dividend stock to a growth-oriented pipeline story.

Roivant Details Multi-Asset Growth Strategy

Roivant Sciences outlined an ambitious three-year pipeline strategy at its 2025 Investor Day, targeting multiple drug launches and regulatory filings. The plan emphasizes a diversified portfolio to fuel its next growth phase, a common theme in the biopharma sector.

Leerink Downgrades BioMarin On Competitive Headwinds

Leerink Partners downgraded BioMarin Pharmaceutical (BMRN) to Market Perform and cut its price target to $60 from $82, citing valuation and competitive pressures. This action reflects broader sector-wide challenges related to competition, pricing, and patent cliffs impacting major pharmaceutical firms.

FDA Expedites Bristol Myers' Hodgkin Lymphoma Drug Review

The U.S. Food and Drug Administration (FDA) has granted Priority Review to a new combination therapy from Bristol Myers Squibb for classical Hodgkin Lymphoma. This action is part of a broader agency trend toward accelerating the approval of critical new drugs.

Regeneron Stock Climbs on Positive Eylea HD Drug Approval and Strong Dupixent Sales Data

European Commission Approves Sanofi and Regeneron's Dupixent for Chronic Spontaneous Urticaria

Regeneron Stock Surges 29% on Strong Earnings and Key Drug Approvals